DELCATH SYSTEMS, INC. (DCTH) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US24661P8077

Price
14.93 USD
Market cap
518.05 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

DELCATH SYSTEMS, INC. financials

Fiscal year2025
Revenue85.23 m USD
Gross profit73.43 m USD
Operating income660,000.00 USD
EBIT3.51 m USD
Net income2.70 m USD
Diluted EPS – continuing operations0.07 USD

Full history since 1998, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About DELCATH SYSTEMS, INC.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.